Does the media refer more to BEAM or EDIT?

In the previous week, Editas Medicine had 7 more articles in the media than Beam Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 8 mentions for Beam Therapeutics. Editas Medicine's average media sentiment score of 0.69 beat Beam Therapeutics' score of 0.57 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EDIT or CRSP?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 15 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.69 beat CRISPR Therapeutics' score of 0.32 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EDIT or NTLA?

In the previous week, Editas Medicine had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 12 mentions for Intellia Therapeutics. Editas Medicine's average media sentiment score of 0.69 beat Intellia Therapeutics' score of 0.67 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ANAB or EDIT?

AnaptysBio has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $234.60M 5.86 -$13.23M $5.37 8.56 Editas Medicine $40.52M 10.99 -$160.06M -$0.75 N/A

Does the media favor ANAB or EDIT?

In the previous week, Editas Medicine had 10 more articles in the media than AnaptysBio. MarketBeat recorded 15 mentions for Editas Medicine and 5 mentions for AnaptysBio. Editas Medicine's average media sentiment score of 0.69 beat AnaptysBio's score of 0.62 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Editas Medicine 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Editas Medicine (EDIT) Competitors

$2.90 +0.06 (+2.11%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.89 -0.01 (-0.34%)

As of 10/9/2026 07:54 PM Eastern

Compare

EDIT vs. BEAM, CRSP, NTLA, ANAB, and INBX

Should you buy Editas Medicine stock or one of its competitors? Editas Medicine's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), AnaptysBio (ANAB), and Inhibrx Biosciences (INBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Editas Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Beam Therapeutics has a net margin of -54.75% compared to Editas Medicine's net margin of -157.32%. Beam Therapeutics' return on equity of -30.71% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Editas Medicine	-157.32%	-196.63%	-38.17%

Beam Therapeutics has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 71.9% of Editas Medicine shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 3.1% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Editas Medicine had 7 more articles in the media than Beam Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 8 mentions for Beam Therapeutics. Editas Medicine's average media sentiment score of 0.69 beat Beam Therapeutics' score of 0.57 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	19.00	-$79.99M	-$0.86	N/A
Editas Medicine	$40.52M	10.99	-$160.06M	-$0.75	N/A

Beam Therapeutics presently has a consensus target price of $50.10, suggesting a potential upside of 94.94%. Editas Medicine has a consensus target price of $5.83, suggesting a potential upside of 101.15%. Given Editas Medicine's higher possible upside, analysts plainly believe Editas Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Beam Therapeutics beats Editas Medicine on 12 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to CRISPR Therapeutics?

Editas Medicine (NASDAQ:EDIT) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Editas Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.99	-$160.06M	-$0.75	N/A
CRISPR Therapeutics	$3.51M	1,470.73	-$581.60M	-$4.76	N/A

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Editas Medicine. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 15 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.69 beat CRISPR Therapeutics' score of 0.32 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Editas Medicine currently has a consensus target price of $5.83, suggesting a potential upside of 101.15%. CRISPR Therapeutics has a consensus target price of $67.94, suggesting a potential upside of 27.25%. Given Editas Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Editas Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.68

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Editas Medicine has a net margin of -157.32% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Summary

Editas Medicine beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to Intellia Therapeutics?

Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Editas Medicine has a net margin of -157.32% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Editas Medicine has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Editas Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.99	-$160.06M	-$0.75	N/A
Intellia Therapeutics	$67.67M	27.07	-$412.69M	-$3.36	N/A

Editas Medicine currently has a consensus price target of $5.83, suggesting a potential upside of 101.15%. Intellia Therapeutics has a consensus price target of $20.72, suggesting a potential upside of 58.51%. Given Editas Medicine's stronger consensus rating and higher possible upside, equities analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Intellia Therapeutics	5 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.26

In the previous week, Editas Medicine had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 12 mentions for Intellia Therapeutics. Editas Medicine's average media sentiment score of 0.69 beat Intellia Therapeutics' score of 0.67 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Editas Medicine beats Intellia Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Editas Medicine compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Editas Medicine (NASDAQ:EDIT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, Editas Medicine had 10 more articles in the media than AnaptysBio. MarketBeat recorded 15 mentions for Editas Medicine and 5 mentions for AnaptysBio. Editas Medicine's average media sentiment score of 0.69 beat AnaptysBio's score of 0.62 indicating that Editas Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	5.86	-$13.23M	$5.37	8.56
Editas Medicine	$40.52M	10.99	-$160.06M	-$0.75	N/A

AnaptysBio has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Editas Medicine has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

71.9% of Editas Medicine shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by insiders. Comparatively, 3.1% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AnaptysBio has a net margin of 82.37% compared to Editas Medicine's net margin of -157.32%. AnaptysBio's return on equity of 112.00% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	82.37%	112.00%	2.20%
Editas Medicine	-157.32%	-196.63%	-38.17%

AnaptysBio currently has a consensus target price of $77.79, suggesting a potential upside of 69.28%. Editas Medicine has a consensus target price of $5.83, suggesting a potential upside of 101.15%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Editas Medicine is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

AnaptysBio beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Editas Medicine compare to Inhibrx Biosciences?

Editas Medicine (NASDAQ:EDIT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

In the previous week, Editas Medicine had 14 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 15 mentions for Editas Medicine and 1 mentions for Inhibrx Biosciences. Editas Medicine's average media sentiment score of 0.69 beat Inhibrx Biosciences' score of 0.37 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Editas Medicine	Positive
Inhibrx Biosciences	Neutral

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Editas Medicine has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.81, indicating that its share price is 281% more volatile than the broader market.

Inhibrx Biosciences has a net margin of 0.00% compared to Editas Medicine's net margin of -157.32%. Editas Medicine's return on equity of -196.63% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Inhibrx Biosciences has lower revenue, but higher earnings than Editas Medicine. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.99	-$160.06M	-$0.75	N/A
Inhibrx Biosciences	$1.30M	1,075.81	-$140.05M	-$8.88	N/A

Editas Medicine presently has a consensus price target of $5.83, suggesting a potential upside of 101.15%. Inhibrx Biosciences has a consensus price target of $197.50, suggesting a potential upside of 107.87%. Given Inhibrx Biosciences' higher probable upside, analysts plainly believe Inhibrx Biosciences is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Editas Medicine beats Inhibrx Biosciences on 9 of the 17 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDIT vs. The Competition

Export

Metric	Editas Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$445.38M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-3.87	13.55	274.99	26.14
Price / Sales	10.99	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	10.36	17.17	11.22	6.33
Net Income	-$160.06M	-$22.69M	$3.50B	$382.15M
7 Day Performance	10.69%	-1.34%	-0.89%	-1.40%
1 Month Performance	9.43%	-8.45%	-4.42%	-3.47%
1 Year Performance	-22.04%	14.02%	7.03%	1.18%

Editas Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDIT Editas Medicine	2.4432 of 5 stars	$2.90 +2.1%	$5.83 +101.1%	-28.9%	$445.38M	$40.52M	N/A	87	Trending News Analyst Upgrade
BEAM Beam Therapeutics	2.1615 of 5 stars	$24.52 +1.2%	$49.00 +99.8%	-7.8%	$2.50B	$139.74M	N/A	540
CRSP CRISPR Therapeutics	3.4422 of 5 stars	$56.00 +3.5%	$67.94 +21.3%	-28.7%	$5.23B	$11M	N/A	393	Trending News Analyst Forecast Insider Trade
NTLA Intellia Therapeutics	3.2968 of 5 stars	$12.03 +5.3%	$20.98 +74.4%	-48.7%	$1.60B	$59.51M	N/A	377	News Coverage Analyst Forecast
ANAB AnaptysBio	3.8081 of 5 stars	$50.37 -0.8%	$79.15 +57.1%	+44.6%	$1.52B	$232.39M	9.38	104

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDIT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, ANAB, and INBX

How does Editas Medicine compare to Beam Therapeutics?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Summary

How does Editas Medicine compare to AnaptysBio?

Summary

How does Editas Medicine compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Editas Medicine (EDIT) Competitors

EDIT vs. BEAM, CRSP, NTLA, ANAB, and INBX

How does Editas Medicine compare to Beam Therapeutics?

Is BEAM or EDIT more profitable?

Which has more volatility & risk, BEAM or EDIT?

Do institutionals and insiders hold more shares of BEAM or EDIT?

Does the media refer more to BEAM or EDIT?

Which has better earnings & valuation, BEAM or EDIT?

Do analysts prefer BEAM or EDIT?

Summary

How does Editas Medicine compare to CRISPR Therapeutics?

Which has stronger earnings & valuation, EDIT or CRSP?

Does the media prefer EDIT or CRSP?

Which has more volatility & risk, EDIT or CRSP?

Do analysts recommend EDIT or CRSP?

Do insiders & institutionals hold more shares of EDIT or CRSP?

Is EDIT or CRSP more profitable?

Summary

How does Editas Medicine compare to Intellia Therapeutics?

Is EDIT or NTLA more profitable?

Which has more volatility & risk, EDIT or NTLA?

Do insiders and institutionals hold more shares of EDIT or NTLA?

Which has stronger valuation and earnings, EDIT or NTLA?

Do analysts rate EDIT or NTLA?

Does the media prefer EDIT or NTLA?

Summary

How does Editas Medicine compare to AnaptysBio?

Does the media favor ANAB or EDIT?

Which has higher valuation and earnings, ANAB or EDIT?

Which has more risk & volatility, ANAB or EDIT?

Do institutionals & insiders hold more shares of ANAB or EDIT?

Is ANAB or EDIT more profitable?

Do analysts recommend ANAB or EDIT?

Summary

How does Editas Medicine compare to Inhibrx Biosciences?

Does the media prefer EDIT or INBX?

Do institutionals and insiders hold more shares of EDIT or INBX?

Which has more risk & volatility, EDIT or INBX?

Is EDIT or INBX more profitable?

Which has higher valuation & earnings, EDIT or INBX?

Do analysts rate EDIT or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT vs. The Competition

Editas Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools